漢港控股(01663.HK)附屬公司實驗室落户杭州醫藥港成功取得新的CNAS認可證書
格隆匯3月22日丨漢港控股(01663.HK)公吿，公司旗下子公司浙江美測醫藥科技有限公司通過中國合格評定國家認可委員會實驗室現場變更評審和定期監督檢查，成功獲得新的實驗室國家認可證書，證書編號為CNASL14242，發證時間為2022年3月9日，有效期為5年。CNAS是中國最具權威性的實驗室認可管理機構。
CNAS認可已經融入國際認可互認體系，在國際認可活動中佔據重要地位。
為配合醫藥研發業務的長遠發展，浙江美測已於2021年9月落户杭州醫藥港。杭州醫藥港位於杭州錢塘新區，是浙江省和杭州市生物醫藥產業的核心區。以生物技術製藥、生物醫學工程、重大疾病化學制藥為細分產業方向，目前已經聚集了輝瑞、默沙東、吉利德、雅培、禮來、拜耳等全球十大藥企中的七家。杭州醫藥港的全鏈式產業生態體系優勢，以及全面優良的配套設施，對浙江美測開展產業協作和拓展下游業務上有莫大裨益，有利於提升浙江美測的行業競爭力和提升業內地位。
落户浙江杭州醫藥港後，浙江美測擁有了更大的實驗室場地、更多的高精頂尖儀器設備、更全面的專業技術人才和更強大的研發團隊的同時，也正式全面開展整體藥學研究服務。在延續原有的方法開發驗證、雜質譜研究、包材相容性研究、工藝組件相容性研究、包裝容器密封性研究、微生物檢測等服務專案的同時，新增了原料藥工藝開發及品質研究、原料藥工藝改進及工藝優化、仿製藥及創新制劑工藝研發服務、化學FTE&FFS服務等業務，覆蓋了仿藥、複雜製劑、創新藥等領域，大幅提升了美測作為藥物研發一站式CRO的服務能力。
由於實驗場地的變更，浙江美測需就CNAS證書進行相應的變更美測實驗室此次成功通過變更評審、獲得新的CNAS證書，標誌着美測實驗室搬遷後不論在權威、公正、專業、合規、檢測設備、設施、檢測技術和管理能力等各方面均達到了國內一流水平，體現了浙江美測在為客户提供藥物研發、分析、檢測等服務時在品質管理和合規性上的強大競爭力。
集團近年致力發展業務多元化，在做好自身房地產業務的同時，亦積極推進醫藥科技研發和大健康產業相關業務，務求構建更廣闊多元的業務組合，從而確保本集團的可持續發展。隨着浙江美測的發展漸趨成熟，實驗室水平持續提升，集團預期浙江美測於未來將能成為拉動本集團業務發展的第二頭馬車。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
